Search Results - "AVERBUCH, Steven"

Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1 by GIACCONE, Giuseppe, HERBST, Roy S, GATZEMEIER, Ulrich, GROUS, John, OCHS, Judith S, AVERBUCH, Steven D, WOLF, Michael K, RENNIE, Pamela, FANDI, Abderrahim, JOHNSON, David H, MANEGOLD, Christian, SCAGLIOTTI, Giorgio, ROSELL, Rafael, MILLER, Vincent, NATALE, Ronald B, SCHILLER, Joan H, VON PAWEL, Joachim, PLUZANSKA, Anna

“…The purpose of this study was to determine whether the addition of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839;…”
Get full text

Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2 by HERBST, Roy S, GIACCONE, Giuseppe, WOLF, Michael K, KREBS, Annetta D, AVERBUCH, Steven D, OCHS, Judith S, GROUS, John, FANDI, Abderrahim, JOHNSON, David H, SCHILLER, Joan H, NATALE, Ronald B, MILLER, Vincent, MANEGOLD, Christian, SCAGLIOTTI, Giorgio, ROSELL, Rafael, OLIFF, Ira, REEVES, James A

“…Preclinical studies indicate that gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington, DE), an orally active epidermal growth factor receptor tyrosine kinase…”
Get full text

Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement by Tsimberidou, Apostolia M, Levit, Laura A, Schilsky, Richard L, Averbuch, Steven D, Chen, Daniel, Kirkwood, John M, McShane, Lisa M, Sharon, Elad, Mileham, Kathryn F, Postow, Michael A

“…To develop recommendations for clinical trial reporting that address the unique efficacy, toxicity, and combination and sequencing aspects of immuno-oncology…”
Get full text

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial by Kris, Mark G, Natale, Ronald B, Herbst, Roy S, Lynch, Jr, Thomas J, Prager, Diane, Belani, Chandra P, Schiller, Joan H, Kelly, Karen, Spiridonidis, Harris, Sandler, Alan, Albain, Kathy S, Cella, David, Wolf, Michael K, Averbuch, Steven D, Ochs, Judith J, Kay, Andrea C

“…CONTEXT More persons in the United States die from non–small cell lung cancer (NSCLC) than from breast, colorectal, and prostate cancer combined. In…”
Get full text

Quantifying factors for the success of stratified medicine by Trusheim, Mark R., Burgess, Breon, Hu, Sean Xinghua, Long, Theresa, Averbuch, Steven D., Flynn, Aiden A., Lieftucht, Alfons, Mazumder, Abhijit, Milloy, Judy, Shaw, Peter M., Swank, David, Wang, Jian, Berndt, Ernst R., Goodsaid, Federico, Palmer, Michael C.

“…Key Points Co-developing a drug with a diagnostic to create a stratified medicine presents challenges for product developers, regulators, payers and…”
Get full text

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer by FUKUOKA, Masahiro, YANO, Seiji, EEK, Richard, HORAI, Takeshi, NODA, Kazumasa, TAKATA, Ichiro, SMIT, Egbert, AVERBUCH, Steven, MACLEOD, Angela, FEYEREISLOVA, Andrea, DONG, Rui-Ping, BASELGA, José, GIACCONE, Giuseppe, TAMURA, Tomohide, NAKAGAWA, Kazuhiko, DOUILLARD, Jean-Yves, NISHIWAKI, Yutaka, VANSTEENKISTE, Johan, KUDOH, Shinzoh, RISCHIN, Danny

“…To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor…”
Get full text

The tyrosine kinase inhibitor ZD1839 (iressa) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells by MOASSER, Mark M, BASSO, Andrea, AVERBUCH, Steven D, RNSEN, Neal

“…The epidermal growth factor receptor (EGFR) is commonly overexpressed in many human tumors and provides a new target for anticancer drug development. ZD1839…”
Get full text

Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial by HERBST, Roy S, MADDOX, Anne-Marie, OCHS, Judith, MUCCI LORUSSO, Patricia, ROTHENBERG, Mace L, SMALL, Eric J, RUBIN, Eric H, BASELGA, Jose, ROJO, Federico, WAUN KI HONG, SWAISLAND, Helen, AVERBUCH, Steven D

“…To investigate safety, tolerability, dose-related pharmacologic properties, and pharmacodynamics of ZD1839 (gefinitib, Iressa; AstraZeneca Pharmacueticals,…”
Get full text

Making the investigational oncology pipeline more efficient and effective: are we headed in the right direction? by LoRusso, Patricia M, Anderson, Aparna B, Boerner, Scott A, Averbuch, Steven D

“…Advances in our knowledge of the molecular mechanisms involved in cancer biology have contributed to an increase in novel target-specific oncology…”
Get full text

Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement by Tsimberidou, Apostolia M, Levit, Laura A, Schilsky, Richard L, Averbuch, Steven D, Chen, Daniel, Kirkwood, John M, McShane, Lisa M, Sharon, Elad, Mileham, Kathryn F, Postow, Michael A

“…To develop recommendations for clinical trial reporting that address the unique efficacy, toxicity, and combination and sequencing aspects of immuno-oncology…”
Get full text

Translating clinical trials into meaningful outcomes by LoRusso, Patricia M, Schnipper, Lowell E, Stewart, David J, Boerner, Scott A, Averbuch, Steven D, Wolf, Walter

“…Efforts to unravel the complex biology that is necessary to develop new therapies best suited for an individual with cancer are at a crossroads with a strained…”
Get full text

Lung cancer prevention: retinoids and the epidermal growth factor receptor-a phoenix rising? by Averbuch, Steven D

Get full text

Improvements in Quality of Life and Disease-related Symptoms in Phase I Trials of the Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Non-Small Cell Lung Cancer and Other Solid Tumors by LORUSSO, Patricia M, HERBST, Roy S, BJORK, Thomas, MADDOX, Anne-Marie, ROTHENBERG, Mace L, SMALL, Eric J, RUBIN, Eric H, FEYEREISLOVA, Andrea, HEYES, Anne, AVERBUCH, Steven D, OCHS, Judith, BASELGA, José, RISCHIN, Danny, RANSON, Malcolm, CALVERT, Hilary, RAYMOND, Eric, KIEBACK, Dirk, KAYE, Stan, GIANNI, Luca, HARRIS, Adrian

“…Purpose: The feasibility and utility of assessing quality of life (QoL) and disease-related symptoms in patients with advanced cancer have been evaluated in…”
Get full text

The Impact of Gefitinib on Epidermal Growth Factor Receptor Signaling Pathways in Cancer by Averbuch, Steven D.

“…The ErbB family of receptor tyrosine kinases, of which the epidermal growth factor receptor (EGFR) is the prototype, is associated with the formation and…”
Get full text

Development of the Novel Biologically Targeted Anticancer Agent Gefitinib by Wolf, Michael, Swaisland, Helen, Averbuch, Steven

“…The emergence of novel, biologically targeted anticancer agents such as gefitinib (‘Iressa’, ZD1839) has raised the question of how the dose for later-stage…”
Get full text

Treatment of Malignant Pheochromocytoma/ Paraganglioma With Cyclophosphamide, Vincristine, and Dacarbazine : Recommendation From a 22-Year Follow-up of 18 Patients by HUI HUANG, ABRAHAM, Jame, HUNG, Elizabeth, AVERBUCH, Steven, MERINO, Maria, STEINBERG, Seth M, PACAK, Karel, FOJO, Tito

“…A long-term follow-up was conducted of 18 patients with a diagnosis of pheochromocytoma/paraganglioma treated with a combination of cyclophosphamide,…”
Get full text

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer by Fukuoka, Masahiro, Yano, Seiji, Giaccone, Giuseppe, Tamura, Tomohide, Nakagawa, Kazuhiko, Douillard, Jean-Yves, Nishiwaki, Yutaka, Vansteenkiste, Johan, Kudoh, Shinzoh, Rischin, Danny, Eek, Richard, Horai, Takeshi, Noda, Kazumasa, Takata, Ichiro, Smit, Egbert, Averbuch, Steven, Macleod, Angela, Feyereislova, Andrea, Dong, Rui-Ping, Baselga, José

“…To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839]; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor…”
Get full text

Abstract CT212: Expanded phase 1/2a study of PLX8394, a novel next generation BRAF inhibitor in patients with advanced, unresectable solid tumors with alterations in BRAF by Janku, Filip, Sherman, Eric, Yaeger, Rona, Parikh, Aparna, Sullivan, Ryan, Feun, Lynn, Fuente, Macarena De La, Tsai, Frank Yung-Chin, Gordon, Michael, Allen, Carl, Rudoltz, Marc S., Balinski, Kathe, Averbuch, Steven, Vidne, Michael, Tarcic, Gabi

“…Abstract The authors did not submit an updated abstract. The original abstract should be considered final. Citation Format: Filip Janku, Eric Sherman, Rona…”
Get full text

Abstract CT143: Pooled analysis of PD-L1 expression across 6 tumor types in the nivolumab clinical program by Krigsfeld, Gabriel, Novotny, James, Oroudjev, Emin, Carnahan, Josette, Zuo, Songlan, Averbuch, Steven D., Burns, Virginia

“…Abstract Introduction: Programmed death ligand 1 (PD-L1) is a key biomarker for PD-1 checkpoint inhibitors; PD-L1 evaluation is incorporated across the…”
Get full text

Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition by Yano, Seiichi, Kondo, Kaoru, Yamaguchi, Motonori, Richmond, Graham, Hutchison, Michael, Wakeling, Alan, Averbuch, Steven, Wadsworth, Peter

“…From immunohistochemical and ligand-binding studies, it is known that the epidermal growth factor receptor (EGFR), a member of the erbB family of receptors, is…”
Get more information